The role of radiotracer imaging in Parkinson disease

Neurology

Volumn 64, Issue 2, 2005, Pages 208-215

  Ravina, B ^a   Eidelberg, D ^b   Ahlskog, J E ^c   Albin, R L ^d   Brooks, D J ^e   Carbon, M ^b   Dhawan, V ^b   Feigin, A ^b   Fahn, S ^f   Guttman, M ^g   Gwinn Hardy, K ^a   McFarland, H ^a   Innis, R ^h   Katz, R G ⁱ   Kieburtz, K ^j   Kish, S J ^g   Lange, N ^k   Langston, J W ^l   Marek, K ^m   Morin, L ^a   Moy, C ^a   Murphy, D ^a   Oertel, W H ⁿ   Oliver, G ^a   Palesch, Y ^o   Powers, W ^p   Seibyl, J ^m   Sethi, K D ^q   Shults, C W ^r   Sheehy, P ^a   Stoessl, A J ^s   Holloway, R ^j   more..

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Northwell Health   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l PARKINSON S INSTITUTE   (United States)

^m Inst for Neurodeg Disorders   (United States)

ⁿ PHILIPPS UNIVERSITY MARBURG   (Germany)

^o MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^p WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q MEDICAL COLLEGE OF GEORGIA   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 BETA CARBOXYMETHOXY 3 BETA (4 IODOPHENYL)TROPANE I 123; DIHYDROTETRABENAZINE; DIHYDROTETRABENAZINE C 11; FLUORODEOXYGLUCOSE F 18; FLUORODOPA F 18; IODINE 123; TRACER; UNCLASSIFIED DRUG;

DIAGNOSTIC TEST; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 19944432710     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000149403.14458.7F     Document Type: Review

References (60)

1. Biomarkers Definitions Work Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
2. New drug, antibiotic and biological drug product regulations: accelerated approval. Proposed rule. 57 Federal Register 13234-13242, 1992.
3. Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 2001;22:485-502.
4. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
5. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
6. Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 1997;20:125-156.
7. Vander Borght TM, Sima AA, Kilbourn MR, et al. [3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995;68:955-962.
8. Kilbourn MR, Kuszpit K, Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 2000;35:250-255.
9. Lehericy S, Brandel JP, Hirsch EC, et al. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res 1994;659:1-9.
10. Uhl RG. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Dis 2003;18:S71-S80.
11. Bezard E, Dovero S., Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-6861.
12. Uhl GR. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994;35:494-498.
13. Counihan TJ, Penny JB Jr. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains. J Neurol Neurosurg Psychiatry 1998;65:164-169.
14. Eidelberg D, Moeller JR, Kazumata K, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997;120:1315-1324.
15. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary 18F-fluorodeoxyglucose and 18F-fluorodopa positron emission tomography studies. Mov Disord 1990;5:203-213.
16. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001;57:2083-2088.
17. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-822.
18. Braak H, Tredici KD, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
19. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
20. Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:431-435.
21. Mentis MJ, McIntosh AR, Feigin A, et al. Relationships between the metabolic patterns that correlated with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 2002;159: 746-754.
22. Dahwan V, Ma Y, Pillai V, et al. Comparative analysis of striatal F-DOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 2002;43:1324-1330.
23. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003;18:S43-S51.
24. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
25. Marek K, Innis R, van Dyck C, et al. [123]Beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
26. Nurmi E, Ruottinen H, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18]fluoro-L-dopa PET study. Mov Disord 2001;16:608-615.
27. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
28. Moeller JR, Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson's disease and normal aging. Brain 1997;120:2197-2206.
29. Moeller JR, Nakamura T, Mentis MJ, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999;40:1264-1269.
30. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
31. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
32. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
33. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
34. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000;55:1540-1547.
35. 123I]-FP-CIT study group. Mov Disord 2000;15:503-510.
36. Benamer HT, Oertel WH, Patterson J, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 2003;18:977-984.
37. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993;33:518-527.
38. 18F]fluorodeoxyglucose and PET. Mov Disord 1998;13:268-274.
39. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187-2195.
40. 123I]β-CIT and SPECT imaging versus clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61:1224-1229.
41. Gatley SJ, Volkow ND, Fowler JS, et al. Positron emission tomography and its use to image the occupancy of drug binding sites. Drug Dev Res 2003;59:194-207.
42. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The result of the Elldopa trial. Neurology 2003;60:A80-A81.
43. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease a randomized controlled trial. JAMA 2000;284:1931-1938.
44. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
45. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease. Arch Neurol 2004;61:1044-1053.
46. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
47. Ahlskog JE. Slowing Parkinson's disease progression, recent dopamine agonist trials. Neurology 2003;60:381-389.
48. Albin RL, Frey KA. Initial agonist treatment of Parkinson disease a critique. Neurology 2003;60:390-394.
49. Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002;360:1767-1769.
50. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/ carbidopa or L-selegiline in striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999;14:436-442.
51. Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. Cereb Blood Flow Metab 2000;20:1604-1609.
52. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-946.
53. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-1564.
54. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
55. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001;50:181-187.
56. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-415.
57. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
58. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
59. Boyd JC. Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest 1997;57:46-63.
60. Holloway RG, Dick AW. Clinical trial end points, on the road to nowhere? Neurology 2002;58:679-686.